Product Code: GMDHC06882CDB
Summary
Global Markets Direct's, 'Amakem NV - Product Pipeline Review - 2015', provides an overview of the Amakem NV's pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Amakem NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of Amakem NV including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Amakem NV's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Amakem NV's pipeline products
Reasons to buy
- Evaluate Amakem NV's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Amakem NV in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Amakem NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Amakem NV and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amakem NV
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Amakem NV and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Amakem NV Snapshot
- Amakem NV Overview
- Key Information
- Key Facts
- Amakem NV - Research and Development Overview
- Amakem NV - Pipeline Review
- Pipeline Products by Stage of Development
- Pipeline Products - Monotherapy
- Amakem NV - Pipeline Products Glance
- Amakem NV - Clinical Stage Pipeline Products
- Phase II Products/Combination Treatment Modalities
- Amakem NV - Early Stage Pipeline Products
- Preclinical Products/Combination Treatment Modalities
- Discovery Products/Combination Treatment Modalities
- Amakem NV - Drug Profiles
- AMA-0076
- Product Description
- Mechanism of Action
- R&D Progress
- AMA-0247
- Product Description
- Mechanism of Action
- R&D Progress
- AMA-0428
- Product Description
- Mechanism of Action
- R&D Progress
- AMA-0526
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules to Inhibit Kinase for Inflammatory Bowel Diseases
- Product Description
- Mechanism of Action
- R&D Progress
- Amakem NV - Pipeline Analysis
- Amakem NV - Pipeline Products by Target
- Amakem NV - Pipeline Products by Route of Administration
- Amakem NV - Pipeline Products by Molecule Type
- Amakem NV - Pipeline Products by Mechanism of Action
- Amakem NV - Recent Pipeline Updates
- Amakem NV - Locations And Subsidiaries
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Amakem NV, Key Information
- Amakem NV, Key Facts
- Amakem NV - Pipeline by Indication, 2015
- Amakem NV - Pipeline by Stage of Development, 2015
- Amakem NV - Monotherapy Products in Pipeline, 2015
- Amakem NV - Phase II, 2015
- Amakem NV - Preclinical, 2015
- Amakem NV - Discovery, 2015
- Amakem NV - Pipeline by Target, 2015
- Amakem NV - Pipeline by Route of Administration, 2015
- Amakem NV - Pipeline by Molecule Type, 2015
- Amakem NV - Pipeline Products by Mechanism of Action, 2015
- Amakem NV - Recent Pipeline Updates, 2015
List of Figures
- Amakem NV - Pipeline by Top 10 Indication, 2015
- Amakem NV - Pipeline by Stage of Development, 2015
- Amakem NV - Monotherapy Products in Pipeline, 2015
- Amakem NV - Pipeline by Top 10 Target, 2015
- Amakem NV - Pipeline by Top 10 Route of Administration, 2015
- Amakem NV - Pipeline by Top 10 Molecule Type, 2015
- Amakem NV - Pipeline Products by Top 10 Mechanism of Action, 2015
